Article info

Download PDFPDF

Correspondence on ‘Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomized, placebo-controlled, phase 3 trial’
Free

Authors

  1. Correspondence to Professor Jin-Xian Huang, University of Hong Kong-Shenzhen Hospital, Shenzhen, China; huangjx{at}hku-szh.org
View Full Text

Citation

Zhao Y, Huang J
Correspondence on ‘Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomized, placebo-controlled, phase 3 trial’

Publication history

  • Received May 11, 2021
  • Accepted May 14, 2021
  • First published June 25, 2021.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.